Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated SARS-CoV-2 (COVID-19) S protein RBD, His,Avitag™ (MALS verified), 25µg  

Recombinant Biotinylated SARS-CoV-2 (COVID-19) S protein RBD, His,Avitag™ (MALS verified), 25µg

Recombinant Biotinylated SARS-CoV-2 (COVID-19) Spike protein RBD, AA Arg 319 - Lys 537, expressed from human 293 cells (HEK293), MALS verified, His, Avitag

Synonyms: Recombinant, Spike, S protein RBD, Spike glycoprotein Receptor-binding domain, S glycoprotein RBD, Spike protein RBD, COVID-19

More details

SPD-C82E9-25

Availability: within 7 days

507,00 €

Background
It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Source
Recombinant Biotinylated SARS-CoV-2 Spike RBD, His,Avitag (SPD-C82E9) is expressed from human 293 cells (HEK293). It contains AA Arg 319 - Lys 537 (Accession # QHD43416.1).
Predicted N-terminus: Arg 319

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 28.2 kDa. The protein migrates as 33-36 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Bioactivity
Please refer to product data sheet.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "A positive selection at binding site 501 in the B.1 lineage might have triggered the highly infectious sub-lineages of SARS-CoV-2"
Tiwary
Gene (2024) 915, 148427
(2) "Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies"
He, An, Zhou et al
Med (2024)
(3) "Specific features of epitope-MIPs and whole-protein MIPs as illustrated for AFP and RBD of SARS-CoV-2"
Zhang, Yarman, Kovács et al
Mikrochim Acta (2024) 191 (5), 242
Showing 1-3 of 4479 papers.